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Abstract
Objectives
To investigate the prevalence of depressive symptoms in rheumatoid arthritis (RA) patients
using two previously validated questionnaires in a large patient sample, and to evaluate
depressive symptoms in the context of clinical characteristics (e.g. remission of disease)
and patient-reported impact of disease.
Methods
In this cross-sectional study, the previously validated Patient Health Questionnaire (PHQ-9)
and Beck-Depression Inventory II (BDI-II) were used to assess the extent of depressive
symptoms in RA patients. Demographic background, RA disease activity score (DAS28),
RA impact of disease (RAID) score, comorbidities, anti-rheumatic therapy and antidepres-
sive treatment, were recorded. Cut-off values for depressive symptomatology were PHQ-9
�5 or BDI-II�14 for mild depressive symptoms or worse and PHQ-9� 10 or BDI-II� 20 for
moderate depressive symptoms or worse. Prevalence of depressive symptomatology was
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Results
In 1004 RA-patients (75.1% female, mean±SD age: 61.0±12.9 years, mean disease dura-
tion: 12.2±9.9 years, DAS28 (ESR): 2.5±1.2), the prevalence of depressive symptoms was
55.4% (mild or worse) and 22.8% (moderate or worse). Characteristics independently asso-
ciated with depressive symptomatology were: age <60 years (OR = 1.78), RAID score >2
(OR = 10.54) and presence of chronic pain (OR = 3.25). Of patients classified as having
depressive symptoms, only 11.7% were receiving anti-depressive therapy.
Conclusions
Mild and moderate depressive symptoms were common in RA patients according to vali-
dated tools. In routine clinical practice, screening for depression with corresponding follow-
up procedures is as relevant as incorporating these results with patient-reported outcomes
(e.g. symptom state), because the mere assessment of clinical disease activity does not suf-
ficiently reflect the prevalence of depressive symptoms.
Clinical trial registration number
This study is registered in the Deutsches Register Klinischer Studien (DRKS00003231) and
ClinicalTrials.gov (NCT02485483).
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease of the musculoskeletal system
that leads to pain, swelling and progressive joint destruction via increased activity of pro-
inflammatory cytokines [1]. Although a variety of conventional and biological disease modify-
ing anti-rheumatic drugs are available to control disease activity in RA, the disease is still chal-
lenging and usually requires life-long treatment. Furthermore, it is associated with a
substantial reduction of overall physical and emotional well-being not only due to articular
symptoms including pain and loss of physical function but also as a result of fatigue and
impaired quality of sleep [1, 2]. This disease burden can affect the patient’s quality of life and
socioeconomic outcomes including workplace absenteeism and presenteeism (low workplace
productivity) [3–5]. For patients with RA, a greater loss of workplace productivity has been
associated not only with functional disability but also with depressive symptoms [6]. More-
over, depression has also been associated with high costs of absenteeism and presenteeism in a
wide range of countries across a variety of socioeconomic statuses [7]. Against this back-
ground, the challenge of depression as a comorbidity of RA becomes evident: in combination,
these disorders pose an even more considerable burden for patients and are likely to result in
more frequent and longer periods of absence. In clinical practice, depressive symptoms and
affective disorders are common in RA [8–10] with a recent meta-analysis reporting 16.8% of
RA patients as having a major depressive disorder [11]. Furthermore, Dougados et al. found
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depression to be the most frequent comorbidity in RA (15%) [12]. Thus, detecting and
addressing depression in patients with RA needs to be a part of patient care. This means,
applying standardized procedures to screen for depression and in the case of positive screening
results, a follow-up with a full diagnostic assessment [13].
A recent meta-analysis emphasized the need for screening tools to be validated against
a clinical interview as gold standard in order to assess depressive symptoms [11]. Follow-
ing these recommendations, we previously evaluated the psychometric properties of the
Patient Health Questionnaire 9 (PHQ-9) [14], the Beck Depression Inventory II (BDI-II)
[15] and the World Health Organization 5-Item Well-Being Index (WHO-5) [16] against a
structured patient interview using the Montgomery-A˚
´
sberg Depression Rating Scale
(MADRS) in RA patients [17]. Within this validation study (VADERA I), we were able to
show that the PHQ-9 and BDI-II are valid and reliable for depression screening in patients
with RA [17]. The aim of the present study–VADERA II–was to use the PHQ-9 and BDI-II
to determine the prevalence of depressive symptoms in RA patients in clinical practice and
to subsequently evaluate the role of covariates such as disease impact measured using the
Rheumatoid Arthritis Impact of Disease (RAID) questionnaire. Although a number of
instruments have been introduced to assess depressive symptoms in rheumatology [11,
18], to the best of our knowledge, VADERA II is the first study within its field to have
explicit validation of self-reporting tools prior to determining prevalence of depressive
symptoms.
Methods
Description of the patient sample
VADERA II was a cross-sectional study. Patients were enrolled from October 2014 to Sep-
tember 2015 at centres in Germany. Inclusion criteria included a documented diagnosis of
RA according to the ACR/EULAR 2010 criteria, age of �18 years, the ability to complete
the questionnaires and scheduling of a RA consultation at one of the participating sites. To
avoid sampling bias and to assure a representative study population, investigators were
informed of the importance of enrolling a practice-oriented and representative sample of
RA patients. There were no exclusions of patients due to RA disease activity, medical treat-
ment or comorbidities. All sites were requested to document the reasons for non-participa-
tion of patients. Institutional review board approval was obtained from the ethics
committee of the Medical Faculty of the Friedrich-Alexander University Erlangen-Nurem-
berg (4431), and all patients completed an informed consent form before participation. This
study is registered in the Deutsches Register Klinischer Studien (DRKS00003231) and Clini-
calTrials.gov (NCT02485483).
The study centres were all members of the working group for the evaluation of systemic
effects of RA (SYRA). The VADERA II study was conducted in 10 centres representing a spec-
trum of clinical settings including large academic medical centres, community hospitals and
private rheumatology practices across Germany. Study participation consisted of a single clinic
visit, which included self-completion of the depression questionnaires.
Sample size considerations for this study were based on a review of the medical literature
for previously reported depression prevalence rates in RA patients. The reported prevalence of
depression in RA patients ranged from 6.4% as reported by Covic et al. in 2012 [19] to 41.5%
as reported by Isik et al. in 2007 [20]. Thus, it was assumed that with the enrolment of 1000
patients, between 64 and 415 patients in the study would have depressive symptomatology,
which would be adequate for the planned analyses.
Prevalence of depressive symptoms and associated risk factors in rheumatoid arthritis
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adherence to PLOS ONE policies on sharing data
and materials.
Study-related procedures and questionnaire cut-points for depressive
symptoms
Data collection in VADERA II was cross-sectional. All data collected in connection with the
VADERA II study were entered in an electronic case report form (eCRF) including the paper-
based BDI-II and PHQ-9 questionnaires [21] and the RAID questionnaire (consisting of seven
items: pain, functional disability, fatigue, sleep, physical well-being, emotional well-being, cop-
ing) [2, 22], all of which were completed during the patient’s study visit. In addition, demo-
graphic data (age, gender, height, weight, family status, educational status and employment
status), RA disease activity according to the Disease Activity Score based on 28 joints and
erythrocyte sedimentation rate (DAS28 (ESR)), laboratory and serologic parameters (CRP,
haemoglobin, ESR, rheumatoid factor and anti-citrullinated protein antibody (ACPA)), and
comorbidities were recorded. Furthermore, information on treatment with anti-rheumatic
therapy in categories (conventional and biological Disease-Modifying Anti-rheumatic Drugs
(cDMARDs/bDMARDs), glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs),
opioids, other medication groups) were recorded as well as anti-depressive treatment in cate-
gories (tricyclic antidepressants (TCAs), serotonin or norepinephrine reuptake inhibitors
(SNRIs), monoamine oxidase inhibitors (MAOIs), psychotherapy, other). Comorbidities at
the time of study participation and potential adverse events were also documented. Standard-
ized cut-offs of the PHQ-9 and the BDI-II as defined by the questionnaire developers [15, 23]
were applied.
Cut-off values for positive depressive symptomatology were PHQ-9�5 or BDI-II�14
which corresponds to the presence of at least mild depressive symptoms. Numbers for the fre-
quency of depressive symptomatology were derived by frequency analysis. Point prevalence
rates (patients with positive depressive symptoms / total study population) and their 95% con-
fidence intervals (CI) were calculated using the Clopper-Pearson (exact) method.
Covariates of depressive symptoms
The risk of depressive symptomatology was further evaluated by taking into account the effects
of other covariates, which were included in univariate and multiple logistic regression analysis.
The potential effects of covariates on the risk of depressive symptomatology were evaluated by
the odds ratio (OR) and 95% CIs. All potentially important covariates were included in a full
model, and a step-down procedure was used to evaluate the impact of the covariates in the
model. The corresponding variables (and arbitrary cut-offs) of interest were as follows: Age
(<60 years,�60 years), sex (0 = female, 1 = male), family status (0 = single, 1 = family), BMI
kg/m2 (0 =<25, 1 =�25), education (ten years of school education or more = 1, less than ten
years of school education = 0), employment (other = 0, 1 = employed), duration of RA (contin-
uous variable), DAS28 (ESR) remission (<2.6,�2.6), RAID patient acceptable symptom state
(PASS) (i.e. RAID�2 vs. RAID >2) [24], presence of chronic pain (0 = no, 1 = yes), presence
of a comorbidity other than mental illness or chronic pain (0 = no, 1 = yes), and current medi-
cation–cDMARD (0 = no, 1 = yes), bDMARD (0 = no, 1 = yes), glucocorticoids (0 = no,
1 = yes), NSAIDs (0 = no, 1 = yes), opiates (0 = no, 1 = yes). Due to indications of multicolli-
nearity in the multiple logistic regression when referring to RAID single numerical rating
scales, we used the PASS criterion for the total score as the outcome of clinical relevance.
The potential effects of RAID single items on the risk of depressive symptomatology were
measured by the OR and 95% CIs addressing distinct symptoms in the univariate analyses.
Sensitivity analyses were conducted using cut-off points for moderate depressive symptoms
as previously defined by the developers of the PHQ-9 and BDI-II questionnaires. In order to
evaluate the impact of the cut-off values of the PHQ-9 and the BDI-II on depression prevalence
Prevalence of depressive symptoms and associated risk factors in rheumatoid arthritis
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and the essential covariates, the cut-off values for moderate depressive symptomatology were
set to a summary score�10 for the PHQ-9 questionnaire and a summary score of�20 for the
BDI-II questionnaire, respectively.
All adverse events (AE), patients experienced between informed consent and completion of
questionnaires were recorded, independent of AE severity or relationship to treatment. Con-
tinuous descriptive results are presented as mean (standard deviation; SD) if not stated other-
wise. Descriptive analysis of nominal characteristics was conducted by referring to frequency
analysis. Statistical analyses were computed using SAS Version 9.4 (SAS; Cary, NC, USA). The
study results are reported according to the STROBE guidelines for observational studies [25].
Results
Patient sample
A total of 1015 patients with RA had given informed consent to the VADERA II study and
1004 patients (99%) completed at least one of the depression questionnaires and were included
in the analysis. During this cross-sectional study, no serious AEs or adverse drug reactions
occurred. Complete questionnaires (all questions answered) were available for evaluation of
the PHQ-9 in 975 patients (97.1%) and the BDI II in 971 patients (96.7%). For the 36 of 1051
screened RA patients (3%) who did not complete the two depression questionnaires, the most
common reasons were: ‘not enough time’ and ‘questions too personal’.
Patient characteristics
Mean patient age was 61.0 (SD 12.9) years; 75.1% were female. The most common family sta-
tus was living with a partner (58.4%), followed by single/living alone (23.5%), or living with
partner and children (16.0%). Amongst others, 52.1% of the patients reported being retired,
39.4% were employed at the time of study participation.
Mean duration of RA in the study population was 12.2 (SD 9.9) years. Serology results indi-
cated that 52.7% of the patients were rheumatoid factor (RF) positive and 61.2% ACPA
positive.
Mean DAS28 (ESR) was 2.5 (SD 1.2) while the median number of both swollen joints and ten-
der joints was 0. The majority of patients (59.1%) were in DAS28 remission (DAS28<2.6). ACR/
EULAR Boolean remission [22] was reported for 25.6% of patients. DAS28 remission was found
in 50.8% of patients having at least mild depressive symptoms in the PHQ-9 or the BDI-II (see
Fig 1A and 1B). On average, the mean RAID score was 3.6 (SD 2.2) with 269 patients (27.0%) ful-
filling RAID PASS with a total score�2 and 728 patients (73.0%) with a RAID score>2.
Presence of a comorbidity at time of participation was reported by 60.9% of patients (58.6%
of patients excluding mental illness). The most common comorbidities were cardiovascular
disease (42.7%) including hypertension (38.1%), diabetes mellitus (9.6%), chronic pain due to
conditions other than RA (9.4%) and chronic respiratory diseases (8.0%). Of the total study
population, 7.5% were receiving anti-depressive therapy.
Details on sample characteristics are shown in Table 1.
Prevalence of depressive symptoms in RA
Overall, the median PHQ-9 score was 5.0 (range 0.0–27.0). Based on the categorized results
from the PHQ-9, 55.1% (95% CI: 51.89–58.23) (537 / 975 patients) of patients reported at least
mild depressive symptoms (Table 2) with the following distribution across the predefined cate-
gories: 44.9% (none), 34.2% (mild), 15.5% (moderate), 3.6% (moderately severe), and 1.8%
(severe). The median BDI-II score was 8.0 (range 0.0–56.0). Based on the categorized results
Prevalence of depressive symptoms and associated risk factors in rheumatoid arthritis
PLOS ONE | https://doi.org/10.1371/journal.pone.0217412 May 28, 2019 5 / 13
from the BDI-II, 27.7% (95% CI: 24.91–30.63) (269 / 971 patients) of the RA patients had at
least mild depressive symptoms (Table 2) while 20.4% had minimal depressive symptoms,
which was below the predefined cutpoint of interest in this study. Point prevalence rates for
depressive symptoms based on the BDI-II were as follows: 51.9%, (none), 20.4% (minimal),
15.7% (mild), 7.8% (moderate), and 4.2% (severe).
Characteristics related to depressive symptoms in RA
The unadjusted ORs and the 95% CIs for the risk of depressive symptoms stratified by covari-
ates suggested that age (<60 years), BMI (�25), not being in DAS28 remission (DAS28 (ESR)
�2.6), a RAID total score >2, steroid use, NSAID use, opiate use and presence of chronic pain
lead to a higher risk of having depressive symptoms. Gender, RA disease duration, family sta-
tus, education, employment, cDMARDs, bDMARDs and the presence of comorbidity exclud-
ing mental illness or chronic pain were not related to depressive symptoms in the univariate
analyses. ORs obtained by multiple logistic regression which adjusted for all other covariates
in the model, confirmed that age (<60 years), a RAID total score >2 and presence of chronic
pain lead to a statistically significant higher risk of having depressive symptoms. In this con-
text, not having RAID PASS (i.e. RAID total score >2) seemed to be the most important risk
factor (OR: 10.54, 95% CI: 6.87–16.16) followed by presence of chronic pain (OR: 3.25, 95%
CI: 1.65–6.39) and age < 60 years (OR: 1.78, 95% CI: 1.13–2.80). This pattern of results was
found for the ORs given for both at least mild depressive symptoms (BDI-II�14 or PHQ-9
�5) and at least moderate depressive symptoms (BDI-II�20 or PHQ-9�10), whereas the
results for RAID PASS showed considerably increased ORs in both the univariate and multiple
analyses (Table 3). Furthermore, the univariate RAID single item analysis addressing distinct
symptoms indicated that all items were related to the occurrence of depressive symptoms
Fig 1. A/1B BDI-II and PHQ-9 scores by DAS28 (ESR). Legend: (Fig 1A) DAS28 (ESR) scores by BDI-II score with black lines showing cut-point for mild
depression and low disease activity. (Fig 1B) DAS28 (ESR) scores by PHQ-9 score with black lines showing cut-point for mild depressive symptoms and low
disease activity.
https://doi.org/10.1371/journal.pone.0217412.g001
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(Table 4). The step-down multiple regression procedure verified significance of RAID score,
chronic pain and age, and showed that NSAID medication was marginally significant for at
least moderately depressive symptoms (OR: 1.47 95% CI: 1.02–2.13).
Discussion
To the best of our knowledge, this is the first time the RAID questionnaire and its PASS crite-
rion have been applied to a study addressing depressive symptoms in RA. Furthermore, this is
the first time depression questionnaires that were previously validated specifically in RA
patients have been used in a prevalence study.
In summary, our findings show that depressive symptoms measured with previously vali-
dated questionnaires are common in RA, with frequencies ranging from 12.0% (at least mod-
erate, BDI-II) to 55.1% (at least mild, PHQ-9), depending on the respective category threshold
and the questionnaire’s level of detail. In both severity categories of interest, the BDI-II as tool
with a higher level of detail, returned lower frequencies of depressive symptoms compared to
the PHQ-9. Moreover, the frequency of depressive symptoms on the PHQ-9 in the present
Table 1. Study population characteristics.
PHQ-9 or BDI-II indicating depressive symptoms PHQ-9 or BDI-II not indicating depressive symptoms Total
Characteristics (N = 556) (N = 448) (N = 1004)
Years of age [Mean (SD)] 60.2 (12.2) 62.0 (13.5) 61.0 (12.9)
Gender [n (%)]
Female
Male
429 (77.2%)
127 (22.8%)
325 (72.5%)
123 (27.5%)
754 (75.1%)
250 (24.9%)
Duration of RA in years [Mean (SD)] 12.3 (10.0) 12.1 (9.6) 12.2 (9.9)
Disease Activity Scores
DAS28 (ESR) Score [Mean (SD)] 2.8 (1.3) 2.2 (1.0) 2.5 (1.2)
Boolean Remission [n (%)] 88 (16.3%) 162 (37.2%) 250 (25.6%)
RAID score [Mean (SD)] 4.6 (1.9) 2.3 (1.7) 3.6 (2.2)
Current RA therapy [n (%)]
cDMARDs 441 (80.6%) 364 (82.2%) 805 (81.3%)
Glucocorticoids 303 (55.4%) 198 (44.7%) 501 (50.6%)
bDMARDs 269 (49.0%) 197 (44.5%) 466 (47.0%)
NSAIDs 233 (42.5%) 131 (29.6%) 364 (36.7%)
Opioids 36 (6.5%) 10 (2.3%) 46 (4.6%)
Presence of a comorbidity [n (%)] 360 (64.7%) 251 (56.0%) 611 (60.9%)
Cardiovascular diseases 239 (43.0%) 190 (42.4%) 429 (42.7%)
Diabetes mellitus 54 (9.7%) 42 (9.4%) 96 (9.6%)
Other chronic pain 73 (13.1%) 21 (4.7%) 94 (9.4%)
Chronic respiratory diseases 47 (8.5%) 33 (7.4%) 80 (8.0%)
Mental illness
(including depression)
54 (9.7%) 10 (2.2%) 64 (6.4%)
Depression 42 (7.6%) 8 (1.8%) 50 (5.0%)
Malignancies 20 (3.6%) 17 (3.8%) 37 (3.7%)
Comorbidity without mental illness 342 (61.5%) 246 (54.9%) 588 (58.6%)
Anti-depressive therapy [n (%)] 65 (11.7%) 10 (2.2%) 75 (7.5%)
a Number (%) of patients with non-missing data unless stated otherwise. Abbreviations: SD = standard deviation, RA = rheumatoid arthritis, DAS = Disease Activity
Score, ESR = erythrocyte sedimentation rate, RAID = Rheumatoid Arthritis Impact of Disease questionnaire, cDMARDs = conventional Disease-Modifying Anti-
rheumatic Drugs, bDMARDs = biological Disease-Modifying Anti-rheumatic Drugs, NSAIDs = Nonsteroidal Anti-inflammatory Drugs
https://doi.org/10.1371/journal.pone.0217412.t001
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study (20.9% at least moderate symptom severity) was lower than in a corresponding meta-
analysis (38.8%) [11]. In our sample, patients lacking PASS according to the RAID question-
naire, patients less than 60 years of age, or patients with chronic pain were prone to depressive
symptoms. The RAID PASS result clearly supports previous findings that highlight the rela-
tionship between pain, fatigue, quality of sleep, coping (all measured in the RAID), and depres-
sive symptomology [26–33].
Applying the BDI-II or the PHQ-9 along with the RAID in clinical routine is likely to bene-
fit patients and rheumatologists not only due to an improved detection of depressiveness but
also by shared decision making with the help of structured patient-reported outcomes incor-
porated into the clinical evaluation. A point that still is frequently neglected in clinical routine.
Outcomes such as the RAID or the PHQ-9 may explain why patients with RA, despite clinical
remission, still might show impaired emotional or physical well-being.
Chronic pain, another explanation for considerably reduced well-being, also increased the
risk of depressive symptoms in our sample. Previous research has shown that inflammation
(with pain as a prominent component) might be triggering depression. Nevertheless, further
proof is needed to determine whether chronic pain is a predictor of depression in RA, vice
versa, or whether the relationship is bidirectional [34–38]. In our sample, moderate depressive
symptoms occurred twice as frequently in patients below 60 years of age compared to patients
aged 60 years and above. A previous meta-analysis found similar results [11]. Accordingly,
depression seems to be more common in phases of personal life frequently characterized by
founding a family, raising children, career development, establishing a work-life balance, and
maintaining health while still working–all of that while facing the everyday burden of RA.
Other commonly discussed covariates such as sex, drug class of anti-rheumatic medication,
comorbidities other than chronic pain and mental illness, or DAS28 remission of RA could
not be confirmed to be related to depressive symptoms.
For follow-up on borderline scores, the authors of the PHQ-9 suggest that not all patients
showing mild depressive symptoms require taking action [14]. However, only 20.7% of our
study participants with positive test results for moderate depressive symptoms in both ques-
tionnaires were previously diagnosed with depression or another mental disorder. Moreover,
merely 11.7% of the patients classified as having depressive symptoms were receiving anti-
Table 2. Point prevalence of depressive symptoms by depression questionnaire(s).
Point Prevalence
% (n / total)
95% CI
�Mild depressive symptoms
PHQ-9 Positive (PHQ-9�5) 55.1% (537 / 975) 51.89–58.23
BDI-II Positive (BDI-II�14) 27.7% (269 / 971) 24.91–30.63
BDI-II�14 or PHQ-9�5 55.4% (556 / 1004) 52.24–58.48
�Moderate depressive symptoms
PHQ-9 Positive (PHQ-9�10) 20.9% (204 / 975) 18.41–23.61
BDI-II Positive (BDI-II�20) 12.0% (117 / 971) 10.07–14.26
BDI-II�20 or PHQ-9�10 22.8% (229 / 1004) 20.25–25.53
a Number (%) of patients with non-missing data
Considering all patients with a BDI-II�14 or a PHQ-9�5, the point prevalence of at least mild depressive symptoms based on one or the other questionnaire was
55.4% (95% CI: 52.24–58.48) (556 / 1004 patients; see Table 2). Using more restrictive cut-points indicating at least moderate depressive symptoms, i.e. BDI-II�20 or
PHQ-9�10, the point prevalence was 22.8% (95% CI 20.25–25.53) (229 / 1004 patients) (Table 2).
Patients with at least mild depressive symptoms were less likely to have ACR/EULAR Boolean remission than patients with no depressive symptoms (16.3% vs 37.2%),
and other chronic pain was more frequently reported by these patients than patients with no depressive symptoms (13.1% vs 4.7%).
https://doi.org/10.1371/journal.pone.0217412.t002
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depressive treatment (including psychotherapy) at the time of questioning. This is a clear call
for proactive depression screening. Rheumatologists regularly see patients for routine check-
ups and follow them up, and depression or emotional disturbances can impair RA treatment
adherence [4, 5] [34, 39]. Thus, the rheumatologist’s role in screening for depressive disorders
is crucial for both physical and mental well-being. Nevertheless, screening for depression only
makes sense when coupled with follow-up routines for diagnostic workup and initiation of
anti-depressive therapy [40, 41]. Thus, before the initiation of screening routines, rheumatolo-
gists should collaborate with mental-health professionals and/or therapy coordination services
to establish efficient transfer of patients with depressive symptomology. The screening work-
flow should fit the clinical routine and address results indicating depressiveness at the very
same patient visit. There should also be routines planned in case of a patient reporting suicidal
Table 3. Odds ratios of at least mild or moderate depressive symptoms by patient and RA-related characteristics.
�Mild
Odds Ratio (95% CI)
�Moderate
Odds Ratio (95% CI)
Influence Variable Unadjusted Adjusted Unadjusted Adjusted
Age
(1: <60, 0:�60)
1.50
(1.16–1.93)
1.78
(1.13–2.80)
1.76
(1.31–2.37)
2.16
(1.31–3.56)
Sex
(0 = female, 1 = male)
0.78
(0.59
- 1.04)
0.93
(0.63–1.36)
0.88
(0.62–1.25)
0.96
(0.62–1.50)
Family status
(family = 1, alone = 0)
1.00
(0.74–1.34)
1.07
(0.72–1.59)
0.99
(0.70–1.42)
1.20
(0.75–1.93)
BMI (kg/m2)
(�25 = 1, <25 = 0)
1.49
(1.15–1.93)
1.09
(0.77–1.55)
1.27
(0.93–1.74)
1.02
(0.68–1.53)
Education
(>10 years = 1,�10 years = 0)
0.97
(0.75–1.27)
0.98
(0.70–1.38)
0.80
(0.59–1.10)
0.75
(0.51–1.10)
Employment
(employed = 1, other = 0)
1.09
(0.84–1.41)
1.14
(0.73–1.79)
1.22
(0.90–1.64)
1.11
(0.68–1.82)
RA Duration
(years)
1.00
(0.99–1.02)
1.00
(0.98–1.01)
0.99
(0.97–1.00)
0.99
(0.97–1.01)
DAS28 (ESR)
(<2.6,�2.6)
2.13
(1.61–2.80)
1.27
(0.90–1.80)
1.89
(1.37–2.61)
1.34
(0.91–1.97)
RAID Score
(�2, >2)
11.34
(7.94–16.21)
10.54
(6.87–16.16)
19.23
(8.43–43.86)
13.61
(5.80–31.92)
cDMARDs
(yes = 1, no = 0)
0.90
(0.65–1.25)
0.88
(0.57–1.37)
0.75
(0.52–1.08)
0.62
(0.39–1.00)
bDMARDs
(yes = 1, no = 0)
1.20
(0.93–1.54)
0.99
(0.69–1.42)
1.07
(0.79–1.44)
0.83
(0.55–1.26)
Glucocorticoids medication
(yes = 1, no = 0)
1.54
(1.19–1.98)
1.03
(0.74–1.44)
1.50
(1.11–2.03)
1.02
(0.70–1.49)
NSAID medication
(yes = 1, no = 0)
1.76
(1.35–2.30)
1.24
(0.87–1.75)
1.74
(1.29–2.35)
1.42
(0.97–2.08)
Opiates medication
(yes = 1, no = 0)
3.03
(1.49–6.18)
1.50
(0.64–3.48)
2.77
(1.51–5.06)
1.67
(0.79–3.55)
Comorbidity without mental illness or chronic pain
(0 = no, 1 = yes)
0.79
(0.62–1.02)
1.03
(0.71–1.49)
0.81
(0.60–1.09)
1.18
(0.77–1.81)
Chronic pain
(0 = no, 1 = yes)
3.07
(1.86–5.08)
3.25
(1.65–6.39)
2.55
(1.64–3.97)
2.90
(1.55–5.43)
aReference category for ORs: age�60, female sex, DAS28 <2.6, RAID�2, no for each type of RA medication, and no for presence of a comorbidity without mental
illness or chronic pain, no for chronic pain. Adjusted odds ratios adjusted in multiple logistic regression for other covariates in table. Abbreviations: RA = rheumatoid
arthritis, DAS = Disease Activity Score, ESR = erythrocyte sedimentation rate, RAID = Rheumatoid Arthritis Impact of Disease questionnaire
https://doi.org/10.1371/journal.pone.0217412.t003
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ideations. This is especially pertinent for resident rheumatologists without instant access to the
hospital environments.
Although we were able to recruit a patient sample from a wide variety of rheumatologic
facilities in Germany, the reproducibility of our results and their practical application may be
limited to the situation in Western Europe. Worldwide generalization of our results may not
be possible due to differences in culture, health care system and limited availability of anti-
rheumatic treatment. The low disease activity in our sample (e.g. median ESR: 14mm/h,
median CRP: 0 mg/dl, median TJC: 0, median SJC: 0)–likely the result of adequate clinical care
and sufficient access to effective bDMARDs–may accurately reflect treatment at German cen-
tres, but may also limit the generalizability of these results to large populations of patients with
severe RA and patients with early or persistent RA. Furthermore, to ensure comparability with
other studies, analysis of these data used standard PHQ-9�5 and BDI-II�14 cut-offs to deter-
mine mild depressive symptomology. Validation of these instruments specifically in RA
patients found mild depressive symptomology cut-offs to be PHQ-9�6 and BDI-II�12 [17].
Overall, we think that these data are robust and therefore translate to other countries with
good access to anti-rheumatic therapy. Especially as these data show that despite good control
of inflammatory symptoms of RA, comorbid depression constitutes a significant burden for
patients. Coupling depression screening routines with consultation by a mental health profes-
sional at the same visit may already suffice to lower unrecognized episodes of depression and
improve clinical outcomes.
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